02/10
Headlines

ALDR

Hot News : Alder Biopharmaceuticals Inc. (NASDAQ:ALDR), CalAmp Corp. (NASDAQ:CAMP), Phillips 66 (NYSE:PSX), HEICO Corporation (NYSE:HEI), BlackBerry Ltd (NASDAQ:BBRY)

Mark Doerr03 mins

Alder BioPharmaceuticals (NASDAQ:ALDR) announced data from the proof-of-concept clinical trial of ALD403 published in the October 6, 2014 issue of Lancet Neurology demonstrates that ALD403 met the primary study endpoint and is effective for the preventative treatment of migraine. ALD403 is Alder’s lead clinical candidate targeting the calcitonin gene-related peptide, or CGRP, for migraine prevention….

Read More

Biotech Volatile Movements: CEL-SCI (NYSEMKT:CVM), NewLink Genetics (NASDAQ:NLNK), Alder Biopharmaceuticals (NASDAQ:ALDR), CytRx (NASDAQ:CYTR), StemCells Inc (NASDAQ:STEM)

Kevin Long03 mins

CEL-SCI Corporation (NYSEMKT:CVM) announced that Geert Kersten Chief Executive Officer will be presenting at the 2014 BIO International Convention on Wednesday June 25th at 2:00 p.m. PDT. Hosted by the Biotechnology Industry Organization (BIO) this year’s global event for biotechnology will take place June 23-26 at the San Diego Convention Center in San Diego California….

Read More

Biotech Decliners: Recro Pharma Inc (NASDAQ:REPH), Ignyta Inc (NASDAQ:RXDX), Alder Biopharmaceuticals Inc (NASDAQ:ALDR), Corcept Therapeutics Incorporated (NASDAQ:CORT)

Mark Doerr03 mins

Aegis started coverage on shares of Recro Pharma Inc. (NASDAQ:REPH) in a research note issued on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $40.00 price target on the stock. Aegis’ price objective suggests a potential upside of 412.16% from the company’s current price. Recro Pharma Inc (NASDAQ:REPH) stock performance was -7.30%…

Read More

Stocks Touched New Highs: Applied Genetic Technologies Corp (NASDAQ:AGTC), Versartis Inc (NASDAQ:VSAR), Orthofix International NV (NASDAQ:OFIX), Alder Biopharmaceuticals Inc (NASDAQ:ALDR), Enzo Biochem, Inc. (NYSE:ENZ)

Kevin Long03 mins

Applied Genetic Technologies Corp (NASDAQ:AGTC) had its price target increased by BMO Capital Markets from $21.00 to $34.00 in a research report sent to investors on Monday morning. The firm currently has an outperform rating on the stock. Applied Genetic Technologies Corp (NASDAQ:AGTC) stock performance was 6.26% in last session and finished the day at…

Read More

Biotech Bullish Stocks: Applied Genetic Technologies (NASDAQ:AGTC), Alder Biopharmaceuticals (NASDAQ:ALDR), Concert Pharmaceuticals (NASDAQ:CNCE), Recro Pharma Inc (NASDAQ:REPH), Relypsa (NASDAQ:RLYP)

Kristen Barton03 mins

BMO Capital Markets boosted their price target on shares of Applied Genetic Technologies Corp (NASDAQ:AGTC) from $21.00 to $34.00 in a research note issued on Monday. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ target price points to a potential upside of 34.44% from the stock’s previous close. Applied Genetic…

Read More